Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-05-01 00:00:00 ET · period of report 2024-04-29 · accession 0001415889-24-011915 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-01 | 2024-04-29 | ELVN | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| DM | 2024-05-01 | 2024-04-29 | ELVN | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $17.91 | -12.0K | 1,013 | -92% | -$214.9K |
| D | 2024-05-01 | 2024-04-29 | ELVN | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $0.00 | -12.0K | 218.6K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-29 | M | A | 12,000 | $1.12 | 12,000 | D | — | — | |
| 2 | Common | Common Stock | 2024-04-29 | S | D | 1,013 | $18.48 | 0 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $18.37 to $18.5795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Common Stock | 2024-04-29 | S | D | 10,987 | $17.86 | 1,013 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $17.369 to $18.3544. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Derivative | Stock Option (right to buy) | 2024-04-29 | M | D | 12,000 | $0.00 | 218,550 | D | $1.12 · — to 2030-06-16 | 12,000 Common Stock | (F5) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |